Drug Profile

Gemlapodect - Noema Pharma

Alternative Names: NOE-105

Latest Information Update: 18 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Developer Noema Pharma
Class Amides; Behavioural disorder therapies; Benzene derivatives; Ketones; Morpholines; Pyrazoles; Pyridines; Small molecules; Triazoles
Mechanism of Action Phosphodiesterase 10A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Gilles de la Tourette's syndrome; Speech disorders

Most Recent Events

18 Sep 2025 Chemical structure information added.
17 Oct 2024 Efficacy and adverse event data from a phase IIa trial in Gilles de la Tourette's syndrome released by Noema Pharma
10 Sep 2024 Phase-II clinical trials in Gilles de la Tourette's syndrome (In adolescents, In adults) in Spain (PO) (NCT06315751)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com